Fate Therapeutics, Inc. (FATE)
After hours:
- Motley Fool
3 Cathie Wood Stocks for the Future
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
- GlobeNewswire
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
TCR-CAR+ iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR-CAR+ iPSC-derived CD8αβ T Cells Compared Favorably with Healthy-donor Peripheral Blood CAR T Cells Phase 1 Study Ongoing of First-ever iPSC-derived T-cell Product Candidate FT819 for Off-the-shelf Treatment of Patients with Relapsed / Refractory B-cell Malignancies SAN DIEGO, Aug. 09, 2022 (GLOBE NEW
- InvestorPlace
7 Small-Cap Stocks to Buy Before the Bull Market Returns
Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term growth potential. However, they are sensitive to rising inflation and interest rate hikes due to tighter profits and weak balance sheets. Therefore these stocks have taken a bigger hit compared to the broader market. The Russell 2000’s performance is a testament to that, so it’s best to pick up s
